Latest Breaking News On - Sun pharmaceuticals industries - Page 14 : comparemela.com

Sun Pharmaceuticals Industries consolidated net profit rises 123 63% in the March 2021 quarter

Sun Pharmaceuticals Industries consolidated net profit rises 123 63% in the March 2021 quarter
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

Particularsquarter endedyear endedmarSun pharmaceuticals industriesQuarter endedyearVar salesCapital marketசூரியன் மருந்துகள் தொழில்கள்வார் விற்பனைமூலதனம் சந்தை

Sun Pharmaceuticals Industries Ltd soars 0 47%, rises for fifth straight session

Sun Pharmaceuticals Industries Ltd is quoting at Rs 657.5, up 0.47% on the day as on 12:44 IST on the NSE. The stock is up 41.26% in last one year as compared to a 56.5% spurt in NIFTY and a 44.48% spurt in the Nifty Pharma. Sun Pharmaceuticals Industries Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 657.5, up 0.47% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.59% on the day, quoting at 14544.75. The Sensex is at 48437.84, down 0.71%. Sun Pharmaceuticals Industries Ltd has risen around 8% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has risen around 9.72% in last one month and is currently quoting at 13469.25, up 0.45% on the day. The volume in the stock stood at 39.03 lakh shares today, compared to the daily average of 87.19 lakh shares in last one month.

Sun pharmaceuticals industries ltdPharmaceuticals industries ltdNifty pharmaCapital marketNifty 50Bse sensexNational stock exchange of indiaSun pharmaPharmaceutical industry in indiaEconomy of indiaStock exchangesGeneric pharmaceuticalsIntegrated circuitsS ampp bse sensex indexSun pharmaceuticals industriesசூரியன் மருந்துகள் தொழில்கள் லிமிடெட்

Tonsillitis Drugs Market Size 2021 Trending News, Industry Growth, Share, Ecosystem Player Profiles,

Search jobs 22-Apr-2021 Tonsillitis Drugs Market Size 2021 Trending News, Industry Growth, Share, Ecosystem Player Profiles, Progression Status And Business Trends To 2028 Data Bridge Market Research added a new research report on Tonsillitis Drugs Market 2021 by Top players, Regions, Type and Application, Forecast to 2028 provides a credible Tonsillitis Drugs market analysis report carries out research and analysis of the market for a certain product/service which includes the investigation into customer inclinations. It carries out the study of various customer capabilities such as investment attributes and buying potential. This market report contains feedback from the target audience to understand their characteristics, expectations, and requirements. The report provides new and exciting strategies for upcoming products by determining the category and features of products that the target audiences will readily accept. The globa

United statesHong kongUnited kingdomSouth africaSaudi arabiaSouth koreaSun pharmaceuticals industriesGlaxosmithkline plcSi groupMarket researchData bridge market researchResearch phasesTeva pharmaceuticals united states incTonsillitis drugs marketTonsillitis drugsBridge market research

Gynecomastia Treatment Market Set for Rapid Growth and Trend, by 2025

Gynecomastia Treatment Market Set for Rapid Growth and Trend, by 2025
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNew zealandSouth koreaSouth africaUnited arab emiratesSaudi arabiaAsia pacificResearch mediaGynecomastia treatment market factor analysis porters fiveCadila pharmaceuticals ltdKee pharma ltdSun pharmaceuticals industries ltdBiochem pharmaceutical industries ltdPeer group analysisNova pharmaceuticals ltd

Sun Pharma arm to acquire 12 5% stake in WRS Bioproducts, Australia

Sun Pharmaceuticals Industries announced that one of the wholly owned subsidiaries of the Company has agreed to acquire by way of allotment to it, 428,571 ordinary shares (equivalent to 12.5% fully diluted equity stake) of WRS Bioproducts, Australia, a company that is developing novel technologies to produce and commercialize supplements and nutraceutical ingredients from diverse algae species in Australia. The cost of acquisition is AUD 2 million. Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader, Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these

Sun pharmaceuticals industriesCapital marketLife sciencesSustainable agricultureSustainable businessSustainable forest managementBse sensexSun pharmaBio productsGeneric pharmaceuticalsWrs bioproductsசூரியன் மருந்துகள் தொழில்கள்மூலதனம் சந்தைவாழ்க்கை அறிவியல்உயிரி தொழில்நுட்பவியல்நிலையான வணிக